Page last updated: 2024-12-07

geniposide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Geniposide is a natural iridoid glycoside found in the fruit of Gardenia jasminoides, a plant traditionally used in Chinese medicine. It has shown various pharmacological activities, including anti-inflammatory, antioxidant, antidiabetic, neuroprotective, and anticancer effects. Research into geniposide's synthesis focuses on optimizing its extraction from natural sources or using bio-synthesis methods. The compound's importance stems from its potential applications in various medicinal fields. Studies on geniposide aim to elucidate its mechanisms of action, optimize its therapeutic efficacy, and develop safe and effective formulations for clinical use.'

Cross-References

ID SourceID
PubMed CID107848
CHEMBL ID462894
CHEBI ID5299
MeSH IDM0051259

Synonyms (35)

Synonym
jasminoidin
169799-41-1
geniposide ,
24512-63-8
C09781
chebi:5299 ,
CHEMBL462894
methyl (1s,4as,7as)-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate
methyl (1s)-1alpha-(beta-d-glucopyranosyloxy)-7-(hydroxymethyl)-1,4aalpha,5,7aalpha-tetrahydrocyclopenta[c]pyran-4-carboxylate
cyclopenta(c)pyran-4-carboxylic acid, 1-(beta-d-glucopyranosyloxy)-1,4a,5,7a-tetrahydro-7-(hydroxymethyl)-, methyl ester, (1s-(1alpha,4aalpha,7aalpha))-
145295qlxy ,
cyclopenta(c)pyran-4-carboxylic acid, 1-(beta-d-glucopyranosyloxy)-1,4a,5,7a-tetrahydro-7-(hydroxymethyl)-, methyl ester, (1s,4as,7as)-
unii-145295qlxy
S2411
AKOS025311228
cyclopenta(c)pyran-4-carboxylic acid, 1-(.beta.-d-glucopyranosyloxy)- 1,4a,5,7a-tetrahydro-7-(hydroxymethyl)-, methyl ester, (1s,4as,7as)-
IBFYXTRXDNAPMM-BVTMAQQCSA-N
methyl (1s,4as,7as)-7-(hydroxymethyl)-1-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate
AB01558902_03
methyl (1s,4as,7ar)-7-(hydroxymethyl)-1-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate
bdbm50478840
genipin 1-glucoside
geniposide, >=98% (hplc)
mfcd16036219
NCGC00346662-04
(1s,4as,7as)-methyl 7-(hydroxymethyl)-1-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate
Q27106709
BRD-K57275767-001-03-2
HMS3884F17
CCG-268498
cyclopenta[c]pyran-4-carboxylic acid, 1-(beta-d-glucopyranosyloxy)-1,4a,5,7a-tetrahydro-7-(hydroxymethyl)-, methyl ester, (1s,4as,7as)-
(1s)-1alpha-(beta-d-glucopyranosyloxy)-7-(hydroxymethyl)-1,4aalpha,5,7aalpha-tetrahydrocyclopenta[c]pyran-4-carboxylic acid methyl ester
NCGC00346662-06
DTXSID101318419
methyl(1s,4as,7as)-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate

Research Excerpts

Overview

Geniposide (GEN) is a natural iridoid compound isolated from Eucommia ulmoides. It is a class of cyclic enol ether terpene glucoside compounds with strong antioxidant, free radical quenching and cancer-inhibiting activities.

ExcerptReferenceRelevance
"Geniposide (GEN) is a natural antioxidant and anti-inflammatory product and plays an important role in the treatment of diabetes and diabetic complications. "( Geniposide Attenuates Hyperglycemia-Induced Oxidative Stress and Inflammation by Activating the Nrf2 Signaling Pathway in Experimental Diabetic Retinopathy.
Du, S; Guo, Y; Li, L; Tu, Y; Wang, Z; Zhang, Y; Zhu, L; Zhu, M, 2021
)
3.51
"Geniposide (GEN) is a natural iridoid compound isolated from Eucommia ulmoides."( Geniposide Ameliorated Dexamethasone-Induced Cholesterol Accumulation in Osteoblasts by Mediating the GLP-1R/ABCA1 Axis.
Chen, Z; Jin, Q; Li, L; Liu, H; Ouyang, J; Shi, W; Wu, L; Xiao, Y; Xu, D; Zhang, D; Zhang, R; Zhang, S; Zheng, Y, 2021
)
2.79
"Geniposide (GEN) is a typical natural iridoid glucoside compound with a series of biological activities, but the poor bioavailability of GEN limits its clinical application."( A geniposide-phospholipid complex ameliorates posthyperuricemia chronic kidney disease induced by inflammatory reactions and oxidative stress.
Chen, JS; Guo, X; Liao, ZX; Liu, C; Liu, JS; Sun, JY; Wang, MM; Wang, MX; Zhang, J; Zhang, MQ, 2022
)
2.16
"Geniposide is a naturally sourced active ingredient that has diverse pharmacological effects and great potential in improving or treating different kinds of diseases. "( The Beneficial Effects of Geniposide on Glucose and Lipid Metabolism: A Review.
Feng, Q; Gao, S, 2022
)
2.46
"Geniposide is a class of cyclic enol ether terpene glucoside compounds with strong antioxidant, free radical quenching and cancer-inhibiting activities."( Network pharmacology-based analysis on geniposide, a component of gardenia jasminoides, beneficial effects to alleviate LPS-induced immune stress in piglets.
Cui, Y; Jia, J; Shan, Z; Wang, Q, 2023
)
1.9
"Geniposide (GEN) is an iridoid glycoside mainly found in"( Geniposide protects against ox-LDL-induced foam cell formation through inhibition of MAPKs and NF-kB signaling pathways.
Chen, Y; Gong, M; Hu, CY; Huang, XY; Li, ZQ; Zhu, ZS, 2019
)
2.68
"Geniposide is a promising anti-inflammatory compound found in Gardenia jasminoides, but its effects on the progression of HCC remain untested."( Direct inhibition of the TLR4/MyD88 pathway by geniposide suppresses HIF-1α-independent VEGF expression and angiogenesis in hepatocellular carcinoma.
Chen, F; Feng, Y; Guo, W; Lao, L; Man, K; Tan, HY; Tsao, SW; Wang, N; Zhang, C; Zhong, Z, 2020
)
1.54
"Geniposide is an iridoid glycoside and has many biological activities such as anti-inflammatory and antioxidant."( Administration of geniposide ameliorates dextran sulfate sodium-induced colitis in mice via inhibition of inflammation and mucosal damage.
Cao, Y; Fu, Y; Li, S; Li, Y; Liu, B; Liu, J; Lu, X; Shen, P; Zhang, N; Zhang, Z, 2017
)
1.51
"Geniposide is an iridoid compound isolated from Gardenia jasminoides Ellis."( Geniposide promotes autophagy to inhibit insulin resistance in HepG2 cells via P62/NF‑κB/GLUT‑4.
Jiang, H; Li, L; Liu, J; Ma, Y; Yan, J, 2017
)
2.62
"Geniposide (GE) is an active component isolated from the fruit of Gardenia jasminoides Ellis that has anti-inflammatory and other pharmacological effects; however, the underlying mechanism of GE action has not been elucidated in rheumatoid arthritis (RA). "( Novel anti-inflammatory target of geniposide: Inhibiting Itgβ1/Ras-Erk1/2 signal pathway via the miRNA-124a in rheumatoid arthritis synovial fibroblasts.
Dai, L; Dai, XJ; Deng, R; Fu, J; Li, F; Wang, WY; Wang, Y; Wu, H; Zhan, X; Zhang, ZR, 2018
)
2.2
"Geniposide (GE) is an iridoid glycoside compound with anti-inflammatory effect. "( UHPLC-MS/MS analysis of sphingosine 1-phosphate in joint cavity dialysate and hemodialysis solution of adjuvant arthritis rats: Application to geniposide pharmacodynamic study.
Feng, L; Hong, W; Jun, F; Li, D; Ran, D; Wenyu, W; Xiang, Z; Xuejing, D; Yan, W; Zhengrong, Z, 2019
)
2.16
"Geniposide is a natural hepatotoxic iridoid glycoside. "( Role of intestinal microbiota-mediated genipin dialdehyde intermediate formation in geniposide-induced hepatotoxicity in rats.
Huang, L; Jiang, N; Li, X; Li, Y; Lu, Y; Pan, H; Shi, F, 2019
)
2.18
"Geniposide is an active ingredient with anti-apoptotic and anti-inflammatory properties. "( Geniposide protects PC12 cells from lipopolysaccharide-evoked inflammatory injury via up-regulation of miR-145-5p.
Dai, Y; Gu, R; Jiang, R; Ma, S; Zhang, C; Zhang, Z, 2019
)
3.4
"Geniposide is an important constituent of Gardenia jasminoides Ellis, a famous Chinese medicinal plant, and has displayed bright prospects in prevention and therapy of hepatic injury (HI). "( Metabolomics and proteomics annotate therapeutic properties of geniposide: targeting and regulating multiple perturbed pathways.
Han, Y; Sun, H; Sun, W; Wang, X; Yan, G; Zhang, A, 2013
)
2.07
"Geniposide is a bioactive substance derived from gardenia, which has been used in traditional Chinese preparation, such as "Xing-Nao-Jing" (XNJ) for stroke treatment. "( The effect of stroke and other components in Xing-Nao-Jing on the pharmacokinetics of geniposide.
Bai, J; Cao, YF; Du, Q; Du, SY; Guo, YW; Lu, Y; Xu, P, 2014
)
2.07
"Geniposide is a medicine isolated from Gardenia jasminoides Ellis, which is a traditional Chinese herb that is widely used in Asia for the treatment of inflammation, brain diseases, and hepatic disorders. "( Geniposide plays an anti-inflammatory role via regulating TLR4 and downstream signaling pathways in lipopolysaccharide-induced mastitis in mice.
Cao, Y; Fu, Y; Jiang, H; Song, X; Wang, T; Yang, Z; Zhang, N; Zhang, W; Zhang, Z, 2014
)
3.29
"Geniposide is an ingredient in Chinese traditional medicine with few known side effects and shows potential as a drug treatment for Parkinson's disease."( Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease.
Chen, Y; Hölscher, C; Li, L; Zhang, Y, 2015
)
1.44
"Geniposide is an agonist of GLP-1 receptor, but its role in cardiac hypertrophy remains completely unknown."( Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor / AMPKα signalling pathway.
Bian, ZY; Dai, J; Liao, HH; Ma, ZG; Tang, QZ; Yuan, Y; Zhang, N; Zhang, WB, 2016
)
1.42
"Geniposide is a potential therapeutic drug for cardiac hypertrophy."( Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor / AMPKα signalling pathway.
Bian, ZY; Dai, J; Liao, HH; Ma, ZG; Tang, QZ; Yuan, Y; Zhang, N; Zhang, WB, 2016
)
1.42
"Geniposide is a key iridoid glycoside from Gardenia jasminoides fructus widely used in traditional Chinese herbal medicine. "( In Vitro Selection of DNA Aptamers that Binds Geniposide.
Chang, D; Hua, Q; Li, F; Li, W; Li, Y; Wang, X; Zhang, A; Zhang, Z, 2017
)
2.16
"Geniposide is an iridoid glycoside isolated from the fruit of Gardenia jasminoides Ellis used as a Chinese traditional medicine for treatment of generalized vitiligo. "( Geniposide enhances melanogenesis by stem cell factor/c-Kit signalling in norepinephrine-exposed normal human epidermal melanocyte.
Lan, W; Lan, WJ; Wang, HY; Wang, KY, 2008
)
3.23
"Geniposide is an iridoid glucoside extracted from Gardenia jasminoides Ellis fruits and has been reported to have a hypoglycemic effect."( Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin.
Liu, ZQ; Lü, L; Rao, JJ; Wang, GF; Wu, SG; Wu, SY; Xu, W; Zhang, JJ, 2009
)
1.48
"Geniposide is an effective hypoglycemic agent in diabetic mice. "( Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin.
Liu, ZQ; Lü, L; Rao, JJ; Wang, GF; Wu, SG; Wu, SY; Xu, W; Zhang, JJ, 2009
)
2.2
"Geniposide is an iridoid glycoside extracted from the fruits of Gardenia jasminoides, which are used as a food colorant and as a traditional Chinese medicine for treatment of hepatic and inflammatory diseases. "( Modulation of cytochrome P-450-dependent monooxygenases, glutathione and glutathione S-transferase in rat liver by geniposide from Gardenia jasminoides.
Chen, YC; Kang, JJ; Liu, TY; Ueng, TH; Wang, HW,
)
1.78

Effects

Geniposide has been widely found to ameliorate many metabolic diseases. It has been proven to have a therapeutic effect on ulcerative colitis in animals. The potential mechanism in UC remains to be clarified.

ExcerptReferenceRelevance
"Geniposide has been widely found to ameliorate many metabolic diseases. "( Geniposide suppresses thermogenesis via regulating PKA catalytic subunit in adipocytes.
Fan, M; Guan, Y; Li, Y; Liu, J; Liu, S; Nie, C; Qian, H; Wang, L; Yan, Y; Ying, H; Zhang, K, 2021
)
3.51
"Geniposide (GEN) has been considered as one of the effective compounds responsible for the therapeutic efficacy of Eucommia ulmoides against OP."( Geniposide ameliorated dexamethasone-induced endoplasmic reticulum stress and mitochondrial apoptosis in osteoblasts.
Chen, Z; Jiao, L; Li, L; Ouyang, J; Peng, F; Ren, Q; Shi, W; Tang, C; Wang, M; Wu, L; Xiao, Y; Zhang, D; Zhang, S; Zheng, Y; Zhong, B, 2022
)
2.89
"Geniposide (GNP) has been reported to exert neuroprotective effects by reducing oxidative injury and neurocyte apoptosis."( Geniposide attenuates early brain injury by inhibiting oxidative stress and neurocyte apoptosis after subarachnoid hemorrhage in rats.
Cai, J; Cen, X; Li, S; Li, Y; Lu, A; Sun, S; Wu, S; Xiao, X; Zhao, J, 2022
)
2.89
"Geniposide (GE) has been shown to exert anti-inflammatory effects."( Geniposide inhibits SphK1 membrane targeting to restore macrophage polarization balance in collagen-induced arthritis mice.
Bu, YH; Chen, FY; Deng, R; Dong, XT; Gan, PR; Ke, JT; Wang, RH; Wu, H, 2022
)
2.89
"Geniposide has been proven to have a therapeutic effect on ulcerative colitis (UC) in animals, but its potential mechanism in UC remains to be clarified. "( Geniposide promotes splenic Treg differentiation to alleviate colonic inflammation and intestinal barrier injury in ulcerative colitis mice.
Bian, Y; Dou, DH; Gu, Y; Shi, JX; Shi, L; Yu, B; Yu, Y; Yuan, DP, 2022
)
3.61
"As Geniposide (GE) has potent immuno-modulation function, we investigated the effects on the dynamic balance of angiogenesis-related factors and Sphingosine kinase 1 (SphK1)-S1P-S1P receptor 1 (S1PR1) signal transduction in adjuvant-induced arthritis (AA) rats."( Sphingosine kinase 1/sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 pathway: A novel target of geniposide to inhibit angiogenesis.
Bu, Y; Deng, R; Sun, M; Wang, Y; Wu, H; Zhang, H; Zhang, Z, 2020
)
1.29
"Geniposide has been reported to possess pleiotropic activities against different diseases."( Geniposide ameliorated sepsis-induced acute kidney injury by activating PPARγ.
Liu, J; Shi, G; Wang, H; Zhao, N, 2020
)
2.72
"Geniposide (GE) has anti-inflammatory, hepatoprotective, and cholagogic effects."( Geniposide suppresses liver injury in a mouse model of DDC-induced sclerosing cholangitis.
Chen, R; He, P; Li, R; Lin, Y; Liu, Y; Wen, M; Wu, F, 2021
)
2.79
"Geniposide and genipin have been found in Gardenia jasminoides Ellis, a traditional Chinese medicine that exhibits multiple biological functions. "( The Suppressive Effects of Geniposide and Genipin on Helicobacter pylori Infections In Vitro and In Vivo.
Chang, CH; Hsu, YM; Lai, YJ; Lu, CC; Su, CH; Wu, JB; Yang, JS, 2017
)
2.19
"Geniposide has various pharmacological effects; however, low oral bioavailability limits its clinical utility. "( Pharmacokinetics, tissue distribution and relative bioavailability of geniposide-solid lipid nanoparticles following oral administration.
Cao, J; Hao, J; Liu, K; Wang, F, 2014
)
2.08
"Geniposide has shown neuroprotective and growth-factor like effects in several in vivo and in vitro studies."( Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease.
Chen, Y; Hölscher, C; Li, L; Zhang, Y, 2015
)
1.44
"Geniposide (GP) has broad and diverse bioactivities, but until now it is still unknown whether GP can protect against TG-induced liver injury."( Protective effects of geniposide against Tripterygium glycosides (TG)-induced liver injury and its mechanisms.
Cui, Y; Miao, M; Qu, L; Wang, J; Zhang, Y, 2016
)
1.47

Actions

Geniposide could activate energy metabolism signalling pathway (AMPK/SirT1/FOXO1) and reduce H9c2 cell apoptosis. It can lower serum IL-1beta and TNF-alpha levels in rheumatoid arthritis rats.

ExcerptReferenceRelevance
"Geniposide could activate energy metabolism signalling pathway (AMPK/SirT1/FOXO1) and reduce H9c2 cell apoptosis."( Geniposide from
Feng, W; Fu, Y; Gao, L; Hou, Y; Wei, Y; Yuan, P; Zhang, Q; Zheng, X, 2021
)
2.79
"Geniposide could inhibit oxidative stress, reduce apoptosis, protect neuron, and has been used for therapy of the neurodegenerative diseases."( A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases.
Bie, H; Jiang, S; Wang, H; Wang, Y, 2017
)
1.42
"Geniposide can lower serum IL-1beta and TNF-alpha levels in rheumatoid arthritis rats. "( [Effect of geniposide on serum IL-1beta and TNF-alpha of rheumatoid arthritis rats].
Gao, X; Jin, YZ; Sun, WJ; Xie, WL; Zhu, J, 2005
)
2.16

Treatment

Geniposide treatment significantly inhibited cell apoptosis, reduced serum IgG leakage into brain tissue, attenuated astrogliosis and microgliosis, prevented loss of pericytes, loss of tight junction and adherens junction proteins. Geniposid treatment could not only correct the metabolic pattern but could also improve the cognitive dysfunctions and depressive/anxiety symptoms.

ExcerptReferenceRelevance
"Geniposide treatment significantly inhibited cell apoptosis, reduced serum IgG leakage into brain tissue, attenuated astrogliosis and microgliosis, prevented loss of pericytes, loss of tight junction and adherens junction proteins."( Geniposide attenuates neonatal mouse brain injury after hypoxic-ischemia involving the activation of PI3K/Akt signaling pathway.
Liu, F; Liu, Z; Wang, Y; Xue, Y; Yao, W; Zhou, J, 2019
)
2.68
"Geniposide treatment inhibited medulloblastoma cell viability, proliferation, migration, and invasion, but promoted cell apoptosis. "( Geniposide exhibits anticancer activity to medulloblastoma cells by downregulating microRNA-373.
Chen, Z; Liang, X; Liu, W; Qin, Z; Tian, G, 2020
)
3.44
"Geniposide treatment could not only correct the metabolic pattern but could also improve the cognitive dysfunctions and depressive/anxiety symptoms."( CREB-mediated generation and neuronal growth regulates the behavioral improvement of geniposide in diabetes-associated depression mouse model.
Jia, X; Ren, G; Sun, B; Wu, X; Yang, F, 2021
)
1.57
"Geniposide treatment (100mg/kg ip.) for 8 days after MPTP treatment (30mg/kg ip.) improved the locomotor and exploratory activity of mice (open field), and improved bradykinesia and movement balance of mice (rotarod, swim test)."( Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease.
Chen, Y; Hölscher, C; Li, L; Zhang, Y, 2015
)
1.44
"Geniposide pretreatment increased cell viability, decreased LDH levels in the supernatant, and inhibited cardiomyocyte apoptosis caused by H/R. "( Geniposide Prevents Hypoxia/Reoxygenation-Induced Apoptosis in H9c2 Cells: Improvement of Mitochondrial Dysfunction and Activation of GLP-1R and the PI3K/AKT Signaling Pathway.
Cao, L; Chang, GL; Jiang, YQ; Liu, J; Wang, Y; Zhang, DY, 2016
)
3.32
"Geniposide treatment also decreased AFB1-DNA adduct formation in AFB1-treated animals."( Suppressive effect of geniposide on the hepatotoxicity and hepatic DNA binding of aflatoxin B1 in rats.
Lin, JK; Wang, CJ; Wang, SW, 1991
)
1.32
"Pretreatment with geniposide 5, 25, 125 or 625 μmol/L increased cell viability and decreased the apoptosis rate of H"( Geniposide prevents H
Kong, Y; Li, W; Lu, W; Ma, W; Wang, K; Zhang, W; Zhao, Y, 2018
)
2.26
"Treatment with geniposide almost completely blocked the phosphorylation of Smad2/3, extracellular signal-regulated kinase (ERK) and Akt in AML12 cells."( Effects of geniposide on hepatocytes undergoing epithelial-mesenchymal transition in hepatic fibrosis by targeting TGFβ/Smad and ERK-MAPK signaling pathways.
Lee, KY; Park, B; Park, JH; Yoon, J, 2015
)
1.15
"Pretreatment with geniposide markedly improved the cells viability and morphology, decreased the expression of Bax, P53 and caspase-9, and increased the expression of Bcl-2 in PC12 cells challenged by CoCl(2)2. "( Geniposide inhibits CoCl2-induced PC12 cells death via the mitochondrial pathway.
Guo, LX; Liu, JH; Xia, ZN, 2009
)
2.13
"Treatment with geniposide could improve liver histology through reducing the elevated liver index (liver weight/body weight), serum alanine aminotransferase and aspartate aminotransferase. "( Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis.
Huang, C; Li, J; Ma, T; Meng, X; Tang, W; Zha, D; Zong, G, 2011
)
1.02

Toxicity

Slightly increased plasma total bilirubin was considered to be due to interference of metabolite of geniposide with the system of measurement. There were no related changes in histopathology of the liver or in any blood chemistry parameters.

ExcerptReferenceRelevance
" Slightly increased plasma total bilirubin was considered to be due to interference of metabolite of geniposide with the system of measurement and not to be a toxic effect since there were no related changes in histopathology of the liver or in any blood chemistry parameters."( A 13-week oral dose subchronic toxicity study of gardenia yellow containing geniposide in rats.
Chino, M; Hiruma, M; Kitamura, H; Nomura, M; Sato, S; Takei, Y, 2007
)
0.78
"Intestinal microflora (IM) is able to produce toxic and carcinogenic metabolites and induce more potent cytotoxicity against cells than non-metabolites."( Biotransformation of geniposide by human intestinal microflora on cytotoxicity against HepG2 cells.
Ahn, YT; Choi, JH; Do, MT; Jeong, HG; Jeong, TC; Kang, MJ; Kang, W; Khanal, T; Kim, DH; Kim, HG; Kong, MJ; Noh, K; Yeo, HK, 2012
)
0.7
" Initially, toxic effects of geniposide and its metabolite genipin were compared."( Role of metabolism by human intestinal microflora in geniposide-induced toxicity in HepG2 cells.
Ahn, YT; Jeong, HG; Jeong, TC; Kang, MJ; Khanal, T; Kim, DH; Kim, HG; Lee, DH; Lee, YS; Yeo, HK, 2012
)
0.92
" Histopathological examination suggested that no toxic damages were observed in rats treated orally with MG (0."( Evaluation of the Antidepressant Activity, Hepatotoxicity and Blood Brain Barrier Permeability of Methyl Genipin.
Che, X; Fan, H; Wang, M; Wang, T; Wang, W; Xu, H; Yang, M, 2016
)
0.43

Pharmacokinetics

The method has been successfully applied for pharmacokinetic studies of geniposide from rat serum after oral administration of Yin-Zhi-Ku decoction. The results showed that the pharmacokinetics profile (especially the area under the plasma concentration-time curve, AUC) of genipside in type 2 diabetic rats after orally administered with Fructus Gradeniae extract was remarkably different from that in normal rats.

ExcerptReferenceRelevance
" The validated method has been successfully applied for pharmacokinetic studies of geniposide from rat serum after oral administration of Yin-Zhi-Ku decoction."( HPLC method for the determination and pharmacokinetic studies on geniposide in rat serum after oral administration of traditional Chinese medicinal preparation Yin-Zhi-Ku decoction.
Huang, CG; Xu, B; Ye, G; Zhao, HL; Zhu, HY, 2006
)
0.8
" This method was subsequently applied to pharmacokinetic studies of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rats successfully."( Simultaneous determination of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rat serum for the pharmacokinetic investigations by high performance liquid chromatography-tandem mass spectrometry.
Liang, Q; Liu, Q; Luo, G; Pan, Y; Pang, C; Ran, X; Wang, B, 2006
)
0.86
" Finally, the method was successfully applied to the pharmacokinetic study of paeoniflorin in rat brain following a single subcutaneous administration (10 mg/kg) to rats."( Development and validation of a sensitive liquid chromatography-tandem mass spectrometry method for the determination of paeoniflorin in rat brain and its application to pharmacokinetic study.
Chen, DY; Han, XM; Ke, Y; Shen, LL; Shen, R; Sun, XY; Wang, Y; Xia, SM; Yang, YM, 2007
)
0.34
" A successful application of the developed HPLC analysis was demonstrated for the pharmacokinetic study of a Traditional Chinese Medicine formula of Yin Chen Hao Tang preparation."( Simultaneous determination of 6,7-dimethylesculetin and geniposide in rat plasma and its application to pharmacokinetic studies of Yin Chen Hao Tang preparation.
Cao, H; Liu, L; Lv, H; Sun, H; Sun, W; Wang, P; Wang, X, 2008
)
0.59
" The pharmacokinetic parameters were computed by Kinetica software."( [Study on pharmacokinetics of jasminoidin in rabbits administered xingnaojing naristillae by nasal medication].
Chen, X; Du, S; Lu, Y; Wang, Y; Yao, Z, 2010
)
0.36
" Jasminoidin was fitted to a two-compartment open pharmacokinetic model in rabbits."( [Study on pharmacokinetics of jasminoidin in rabbits administered xingnaojing naristillae by nasal medication].
Chen, X; Du, S; Lu, Y; Wang, Y; Yao, Z, 2010
)
0.36
" Pharmacokinetic parameters were calculated from the plasma concentration-time data."( Pharmacokinetics of geniposide in Zhi-Zi-Hou-Pu decoction and in different combinations of its constituent herbs.
Feng, F; Sun, Y; Yu, X, 2012
)
0.7
" In healthy rats, the estimated pharmacokinetic parameters (i."( Simultaneous in vivo RP-HPLC-DAD quantification of multiple-component and drug-drug interaction by pharmacokinetics, using 6,7-dimethylesculetin, geniposide and rhein as examples.
Jiao, G; Sun, H; Sun, W; Wang, X; Yuan, Y; Zhang, A, 2012
)
0.58
"To determine the geniposide in Beagle dogs plasma by HPLC after oral administration or intravenous injection Xingnaojing, and the pharmacokinetic parameters were calculated by the software of Kinetica."( [Pharmacokinetics and bioavailabilities of geniposide in Beagle dogs after oral administration Xingnaojing].
Bian, B; Du, S; Li, P; Tian, X; Wang, H; Yang, J, 2012
)
0.98
" The main pharmacokinetic parameters after oral administration was as follows: Cmax (11."( [Pharmacokinetics and bioavailabilities of geniposide in Beagle dogs after oral administration Xingnaojing].
Bian, B; Du, S; Li, P; Tian, X; Wang, H; Yang, J, 2012
)
0.64
" The investigation showed that there were significant differences in the groups between the normal rat and AA rat in pharmacokinetics parameters, such as the area under the time versus drug concentration curve (AUC(0-∞)) (3."( Comparative pharmacokinetics study after oral administration of geniposide in normal rats and adjuvant-induced arthritis rats by UPLC-MS/MS.
Chen, JY; Hu, SL; Li, H; Shen, C; Wu, H, 2013
)
0.63
" administration of geniposide, the peak concentration of geniposide in plasma occurred at 1 h and plasma geniposide was eliminated nearly completely within 12 h."( Pharmacokinetics, bioavailability and tissue distribution of geniposide following intravenous and peroral administration to rats.
Cao, J; Hao, J; Liu, K; Wang, F, 2014
)
0.97
" A comparative pharmacokinetic study of geniposide in stroke and sham-operated rats after administration of XNJ and geniposide was proceeded to evaluate the effect of stroke on pharmacokinetics of geniposide, while the influence of other components in XNJ was determined by using gardenia extract and geniposide-borneol compounds in rats with stroke to compare."( The effect of stroke and other components in Xing-Nao-Jing on the pharmacokinetics of geniposide.
Bai, J; Cao, YF; Du, Q; Du, SY; Guo, YW; Lu, Y; Xu, P, 2014
)
0.89
" Various pharmacokinetic parameters were estimated from the plasma concentration versus time data using non-compartmental methods."( The effect of stroke and other components in Xing-Nao-Jing on the pharmacokinetics of geniposide.
Bai, J; Cao, YF; Du, Q; Du, SY; Guo, YW; Lu, Y; Xu, P, 2014
)
0.63
" In stroke, the Cmax and AUC(0-t) of geniposide-borneol group and gardenia extraction group were close to XNJ group and geniposide group, respectively."( The effect of stroke and other components in Xing-Nao-Jing on the pharmacokinetics of geniposide.
Bai, J; Cao, YF; Du, Q; Du, SY; Guo, YW; Lu, Y; Xu, P, 2014
)
0.9
" The Cmax value of geniposide in the geniposide-SLNs was significantly higher than that obtained with geniposide solution."( Pharmacokinetics, tissue distribution and relative bioavailability of geniposide-solid lipid nanoparticles following oral administration.
Cao, J; Hao, J; Liu, K; Wang, F, 2014
)
0.96
" The results showed that the pharmacokinetic behaviors of the alkaloids were different although their chemical structures were similar."( Pharmacochemistry and integrated pharmacokinetics of six alkaloids after oral administration of huang-lian-jie-du-tang decoction.
Liu, JX; Ma, ZT; Yang, XW; Zhang, Y, 2014
)
0.4
" The validated method was successfully applied to a pharmacokinetic study of the four bioactive components in rats after intravenous administration of Reduning injection."( Simultaneous determination of neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid and geniposide in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after administration of Reduning injection.
Fu, X; Li, F; Wang, Y; Wang, Z; Wen, J; Xiao, W; Xiong, Z; Zhao, L; Zheng, W, 2015
)
0.64
" The pharmacokinetic parameters were calculated by the software of Kinetica."( [Study on pharmacokinetics of geniposide in mice administrated by xingnaojing microemulsion and mPEG2000-PLA modified xingnaojing microemulsion].
Chen, XL; Du, SY; Guo, QL; Li, HY; Lu, Y; Wen, R, 2014
)
0.69
" The Tmax and mean residence time (MRT) of geniposide of the three groups were consistent with previous data."( Pharmacokinetics of geniposide by monoclonal antibody-based icELISA in mice after oral administration of Huanglian-Jiedu-Tang.
Cheng, JJ; Feng, HB; Qu, HH; Sun, Y; Wang, QG; Wang, XQ; Wu, TT; Zhang, GL; Zhao, Y, 2014
)
0.99
"The aim of this study was to explore the anti-inflammatory effects of Geniposide (GE), an iridoid glycoside compound extracted from Gardenia jasminoides Ellis (GJ) fruit in adjuvant-induced arthritis (AA) rats and its pharmacokinetic (PK) basis."( Anti-inflammatory effects and pharmacokinetics study of geniposide on rats with adjuvant arthritis.
Chen, J; Chen, JY; Dai, MM; Hu, SL; Li, H; Wu, H, 2015
)
0.9
" The pharmacokinetic data demonstrated that the area under concentration-time curve (AUC) values of gentiopicroside, geniposide, baicalin, and swertiamarin were 1417 ± 83."( Determination and pharmacokinetic study of gentiopicroside, geniposide, baicalin, and swertiamarin in Chinese herbal formulae after oral administration in rats by LC-MS/MS.
Lin, LC; Lu, CM; Tsai, TH, 2014
)
0.85
" The present work aimed to assess the impact of mPEG2000-PLA on pharmacokinetic features and brain-targeting ability of XNJ-M."( Xingnaojing mPEG2000-PLA modified microemulsion for transnasal delivery: pharmacokinetic and brain-targeting evaluation.
Bai, J; Du, S; Li, P; Lu, Y; Wen, R; Xu, P; Zhang, Q, 2016
)
0.43
" Hence, the pharmacokinetic-pharmacodynamic (PK-PD) model was introduced in the present study, aiming to link the pharmacokinetic profiles with the therapeutic outcomes of QKLI, and subsequently to provide valuable guidelines for the rational use of QKLI in clinical settings."( Pharmacokinetic-Pharmacodynamic Modeling to Study the Antipyretic Effect of Qingkailing Injection on Pyrexia Model Rats.
Gao, X; Lu, Z; Peng, L; Qin, L; Song, Y; Wang, Q; Zhang, Q; Zhang, Z, 2016
)
0.43
" The results showed that the pharmacokinetic profile (especially the area under the plasma concentration-time curve, AUC) of geniposide in type 2 diabetic rats after orally administered with Fructus Gradeniae extract or pure geniposide was remarkably different from that in normal rats."( Comparative investigation on the pharmacokinetics of geniposide in type 2 diabetic and normal rats after oral administration of Fructus Gradeniae extract.
Chen, R; Deng, YX; He, LH; Li, J; Lv, Y; Zhang, XJ, 2016
)
0.89
" Then, by conducting hypothalamus metabolomics studies, 14 metabolites were screened as the potential biomarkers that related to the antipyretic mechanisms of QKLI and were used as its pharmacodynamic surrogate indices."( An integrated strategy by using target tissue metabolomics biomarkers as pharmacodynamic surrogate indices to screen antipyretic components of Qingkaikling injection.
Fu, S; Gao, X; Huang, Z; Liu, H; Liu, Y; Lu, F; Wang, M; Xie, Z; Yu, H; Zhang, Y; Zhang, Z; Zhao, H, 2017
)
0.46
" Therefore, S1P can also be potentially used as a pharmacodynamic marker to study adjuvant arthritis (AA) rats."( UHPLC-MS/MS analysis of sphingosine 1-phosphate in joint cavity dialysate and hemodialysis solution of adjuvant arthritis rats: Application to geniposide pharmacodynamic study.
Feng, L; Hong, W; Jun, F; Li, D; Ran, D; Wenyu, W; Xiang, Z; Xuejing, D; Yan, W; Zhengrong, Z, 2019
)
0.71
" The pharmacokinetic results demonstrated that the combined administration of ABS and GE( 60 mg·kg~(-1)+60 mg·kg~(-1)) can increase the degree of GE in joint cavity distribution,and the AUCjoint/AUCplasmwere twice of that of single administration of GE( 60 mg·kg~(-1)),which indicated that ABS might played a vital role in GE's distribution to joint cavity."( [Pharmacokinetics of Achyranthes bidentata on adjuvant arthritis rats by microdialysis and UHPLC-MS/MS].
Dai, XJ; Deng, R; Fu, J; Li, F; Wang, WY; Wang, Y; Wu, H; Zhan, X, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
"To screen effective principles from traditional Chinese medicine, a method named hepatocyte extraction combined with HPLC (HE-HPLC) was establish in this study."( [Establishment of hepatocyte extraction combined with HPLC(HE-HPLC) and application in analysis of active components in the fruits of Gardenia jasminoides extract].
Hong, M; Ma, H; Zhu, Q, 2009
)
0.35
" C(max) , AUC and Cl) of D, G and R, when administered with COC (a combination of D, G and R), were C(max) 16."( Simultaneous in vivo RP-HPLC-DAD quantification of multiple-component and drug-drug interaction by pharmacokinetics, using 6,7-dimethylesculetin, geniposide and rhein as examples.
Jiao, G; Sun, H; Sun, W; Wang, X; Yuan, Y; Zhang, A, 2012
)
0.58

Bioavailability

Geniposide has various pharmacological effects; however, low oral bioavailability limits its clinical utility. The results indicated that the oral administration bioavailability of geniposides was in low degree.

ExcerptReferenceRelevance
"5 mL x min(-1), the absorption rate of geniposide remains constant in a dose-independent manner."( [Evaluation of nasal absorption for geniposide solution].
Wan, N; Xu, R; Yang, M; Zhang, H; Zheng, Q, 2009
)
0.9
"According to the P and the logP, it could be indicated that the absorption of geniposide at small intestine was poor absorption; The absorption rate was increased with the decrease of the extract concentration; Their absorption was first-order process besides the passive diffusion mechanism, and facilitated diffusion and active transport may also take part in the transport process."( [Studies on O/W partition coefficient and absorption kinetics of geniposide in fructus gardeniae extract in rat intestine].
Du, S; Lu, Y; Rao, X; Zhang, Q, 2009
)
0.82
" A rat in situ nasal perfusion technique with a novel volumeadjusted calculation was used to examine the absorption rate and extent of Ge."( The in situ and in vivo study on enhancing effect of borneol in nasal absorption of Geniposide in rats.
Chen, X; Du, S; Lu, Y; Wu, Q; Yao, Z; Zhai, Y, 2010
)
0.59
" Compared with the intravenous administration, the absolute bioavailability of Ge was 76."( Enhancing effect of natural borneol on the absorption of geniposide in rat via intranasal administration.
Chen, XL; Du, SY; Lu, Y; Song, X; Wu, Q; Xu, B; Zhai, YS, 2011
)
0.61
" The result illustrated that the oral bioavailability of geniposide was dramatically enhanced when ZZ was combined with HP or/and ZS."( Pharmacokinetics of geniposide in Zhi-Zi-Hou-Pu decoction and in different combinations of its constituent herbs.
Feng, F; Sun, Y; Yu, X, 2012
)
0.95
" In our preliminary study, notoginsenoside R₁ was able significantly to improve the bioavailability of geniposide in beagle dogs, but the underlying mechanisms remain unknown."( The effects of notoginsenoside R₁ on the intestinal absorption of geniposide by the everted rat gut sac model.
Chula, S; Hang, L; Jianning, S; Shi, R; Yinying, B, 2012
)
0.83
"To establish a method for determination of geniposide in Beagle dogs plasma by high performance liquid chromatography (HPLC), and study the pharmacokinetics and bioavailability of geniposide in Beagle dogs after oral administration Xingnaojing."( [Pharmacokinetics and bioavailabilities of geniposide in Beagle dogs after oral administration Xingnaojing].
Bian, B; Du, S; Li, P; Tian, X; Wang, H; Yang, J, 2012
)
0.9
" The bioavailability of geniposide in Beagle dogs after oral administration Xingnaojing was (6."( [Pharmacokinetics and bioavailabilities of geniposide in Beagle dogs after oral administration Xingnaojing].
Bian, B; Du, S; Li, P; Tian, X; Wang, H; Yang, J, 2012
)
0.95
" The results indicated that the oral administration bioavailability of geniposide was in low degree."( [Pharmacokinetics and bioavailabilities of geniposide in Beagle dogs after oral administration Xingnaojing].
Bian, B; Du, S; Li, P; Tian, X; Wang, H; Yang, J, 2012
)
0.87
"The purpose of this study was to investigate the effects of natural borneol (NB) on the pharmacokinetics and bioavailability of ophthalmic administered geniposide (Ge) in rabbits."( Natural borneol enhances geniposide ophthalmic absorption in rabbits.
Bi, H; Guo, J; Liu, D; Song, J; Wang, X; Xie, X, 2013
)
0.89
" The results showed that the constant absorption rate of geniposide (GE) in XNJ-D was (2."( [Comparative study on rat in situ nasal absorption of geniposide of Xingnaojing nasal drop and Xingnaojing microemulsion].
Du, SY; Hao, B; Li, HY; Lu, Y; Wen, R; Zhao, XJ, 2013
)
0.88
"In order to characterize the pharmacokinetics, bioavailability and tissue distribution of geniposide following intravenous and peroral administration to rats, a reliable gradient HPLC-based method has been developed and validated."( Pharmacokinetics, bioavailability and tissue distribution of geniposide following intravenous and peroral administration to rats.
Cao, J; Hao, J; Liu, K; Wang, F, 2014
)
0.86
"The aim of this study was to compare the oral bioavailability and pharmacokinetic data between pure compound of the major active component, single herbal extract and complex herbal formulation by determining bioavailability of geniposide in each group following intravenous and oral administrations."( Comparative oral bioavailability of geniposide following oral administration of geniposide, Gardenia jasminoides Ellis fruits extracts and Gardenia herbal formulation in rats.
Cheng, S; Lin, CH; Lin, LC; Tsai, TH, 2014
)
0.86
"Geniposide has various pharmacological effects; however, low oral bioavailability limits its clinical utility."( Pharmacokinetics, tissue distribution and relative bioavailability of geniposide-solid lipid nanoparticles following oral administration.
Cao, J; Hao, J; Liu, K; Wang, F, 2014
)
2.08
" The curves of time and residual quantities of GP and GPA (lnx) in the intestinal perfusion solution and the cumulative absorption rate were obtained."( Effects of fructus psoraleae extract on the intestinal absorption kinetics of geniposide and geniposidic acid in rat.
Gao, X; Han, L; Hou, X; Huang, Y; Huo, Y; Liu, E; Wang, L, 2014
)
0.63
" These results suggest that the gut microbiota may have an impact on the bioavailability of geniposide."( Effects of intestinal microbiota on the bioavailability of geniposide in rats.
Jin, MJ; Kim, DH; Kim, IS; Yoo, HH, 2014
)
0.87
"A specific, sensitive and high throughput ultra-high performance liquid chromatography-electrospray ionization tandem mass spectrometric method (UHPLC-ESI-MS/MS) was established and validated to assay geniposide (GE), a promising anti-inflammatory drug, in adjuvant arthritis rat plasma: application to pharmacokinetic and oral bioavailability studies and plasma protein binding ability."( Determination of geniposide in adjuvant arthritis rat plasma by ultra-high performance liquid chromatography tandem mass spectrometry method and its application to oral bioavailability and plasma protein binding ability studies.
Chen, J; Dai, MM; Hu, SL; Li, GQ; Li, SP; Sun, LL; Wang, R; Wang, W; Wu, H; Xu, GB, 2015
)
0.94
" The bioavailability and brain-target effects of borneol and geniposide in XNJ-M and XNJ-MM were compared in mice after intravenous (i."( Xingnaojing mPEG2000-PLA modified microemulsion for transnasal delivery: pharmacokinetic and brain-targeting evaluation.
Bai, J; Du, S; Li, P; Lu, Y; Wen, R; Xu, P; Zhang, Q, 2016
)
0.68
" AN could only be detected in the plasma and liver homogenate of normal mice, which was poorly absorbed in OVX mice and low in other measured tissues."( Pharmacokinetics and tissue distribution of five active ingredients of Eucommiae cortex in normal and ovariectomized mice by UHPLC-MS/MS.
An, J; Hu, F; Wang, C; Wang, Z; Yang, L; Zhang, Z, 2016
)
0.43
" The bioavailability of geniposide by nasal route is greater than that by oral administration."( A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases.
Bie, H; Jiang, S; Wang, H; Wang, Y, 2017
)
1.01
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The intestinal absorption study indicated that geniposide was an absorption-enhancer for baicalin and significantly increased the absorption rate constant value and the apparent absorption constant value of baicalin, especially in duodenum and jejunum when the compatibility concentrations were 1:1 and 1:2."( Enhancement effect of geniposide on solubility and intestinal absorption of baicalin.
Cai, Z; Ding, Y; Huang, T; Jin, M; Zhang, T, 2019
)
1.08
" The results showed that GE in plasma of GE-LP displayed three folds longer distribution half-life and a higher bioavailability and brain targeting compared to GE solution."( Geniposide-Loaded Liposomes for Brain Targeting: Development, Evaluation, and In Vivo Studies.
Guan, Y; He, Y; Li, D; Li, N; Li, Y; Liu, S; Long, Y; Shi, A; Shuang, Y; Wan, J; Xiang, Y; Zhang, Y, 2021
)
2.06
" Geniposide (GEN) is a typical natural iridoid glucoside compound with a series of biological activities, but the poor bioavailability of GEN limits its clinical application."( A geniposide-phospholipid complex ameliorates posthyperuricemia chronic kidney disease induced by inflammatory reactions and oxidative stress.
Chen, JS; Guo, X; Liao, ZX; Liu, C; Liu, JS; Sun, JY; Wang, MM; Wang, MX; Zhang, J; Zhang, MQ, 2022
)
2.35

Dosage Studied

The effect of medium dosage of GJE was the best among these three dose groups and also better than Geniposide according to the results of all the detection index.

ExcerptRelevanceReference
" This result was achieved by exerting the levels of dosage in a dose-dependent manner."( Comparisons of geniposidic acid and geniposide on antitumor and radioprotection after sublethal irradiation.
Hsu, HY; Lin, CC; Lin, SY; Yang, JJ, 1997
)
0.57
"3 mg kg(-1) or less did not cause hepatotoxicity even in the repeated dosing study."( Potential hepatotoxicity of geniposide, the major iridoid glycoside in dried ripe fruits of Gardenia jasminoides (Zhi-zi).
Ding, Y; Ji, G; Shi, JR; Tao, JS; Zhang, LY; Zhang, T, 2013
)
0.68
" The pharmacokinetic profiles provide constructive information for the dosage regimen of herbal medicine and also contribute to elucidate the absorption mechanism in herbal applications and pharmacological experiments."( Determination and pharmacokinetic study of gentiopicroside, geniposide, baicalin, and swertiamarin in Chinese herbal formulae after oral administration in rats by LC-MS/MS.
Lin, LC; Lu, CM; Tsai, TH, 2014
)
0.64
" In addition, it was found that GE has rapid absorption and elimination, low absolute bioavailability, high plasma protein binding ability in AA rats after oral administration within the tested dosage range."( Determination of geniposide in adjuvant arthritis rat plasma by ultra-high performance liquid chromatography tandem mass spectrometry method and its application to oral bioavailability and plasma protein binding ability studies.
Chen, J; Dai, MM; Hu, SL; Li, GQ; Li, SP; Sun, LL; Wang, R; Wang, W; Wu, H; Xu, GB, 2015
)
0.76
" The findings obtained would provide fundamental information to propose a more reasonable dosage regimen and improve the level of individualized drug therapy in clinical settings."( Pharmacokinetic-Pharmacodynamic Modeling to Study the Antipyretic Effect of Qingkailing Injection on Pyrexia Model Rats.
Gao, X; Lu, Z; Peng, L; Qin, L; Song, Y; Wang, Q; Zhang, Q; Zhang, Z, 2016
)
0.43
" The absorption of geniposide was studied systematically to guide the design of the oral dosage of geniposide and HLJDT in clinical therapy."( Study on the Absorption Mechanism of Geniposide in the Chinese Formula Huang-Lian-Jie-Du-Tang in Rats.
Guo, L; Yu, D; Zhang, Q; Zhang, Y; Zhu, H, 2017
)
1.06
" The effect of medium dosage of GJE was the best among these three dose groups and also better than Geniposide according to the results of all the detection index."( Learning and memory improvement and neuroprotection of Gardenia jasminoides (Fructus gardenia) extract on ischemic brain injury rats.
Lai, Q; Li, Y; Liu, Y; Yang, M; Zhang, H, 2017
)
0.67
" Rats in the IRI group and sham group were administrated with same dosage of saline at the same time."( Protective Effects of Geniposide on Hepatic Ischemia/Reperfusion Injury.
Huang, HT; Liu, JS; Rong, YP; Wei, L,
)
0.45
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
terpene glycosideA terpenoid in which one or more hydroxy functions are glycosylated.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)IC50 (µMol)500.00000.70004.58049.4500AID1741900
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)500.00000.00053.49849.7600AID1741899
Xanthine dehydrogenase/oxidaseBos taurus (cattle)IC50 (µMol)161.40000.00303.10159.8000AID1867877
Tyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)IC50 (µMol)500.00000.31804.00429.6000AID1741901
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (105)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IITyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of lipid storageTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
B cell differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
T cell differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
erythrocyte differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
glucose homeostasisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of macrophage differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of gluconeogenesisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of inflammatory responseTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of chemotaxisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
regulation of type II interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-6-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-2-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-4-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of macrophage colony-stimulating factor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of positive thymic T cell selectionTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseBos taurus (cattle)
DNA damage checkpoint signalingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
triglyceride metabolic processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
axonogenesisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
brain developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
heart developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
hormone-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cerebellar cortex formationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
platelet formationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
T cell costimulationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of chondrocyte differentiationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of type I interferon productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
microvillus organizationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of interferon-beta productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
multicellular organism growthTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
organ growthTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
megakaryocyte developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
atrioventricular canal developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
ERBB signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
hormone metabolic processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
glucose homeostasisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of protein-containing complex assemblyTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of ossificationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of mitotic cell cycleTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of glucose importTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of insulin secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of protein export from nucleusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of hormone secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
neurotrophin TRK receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
multicellular organismal reproductive processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
genitalia developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
inner ear developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
homeostasis of number of cells within a tissueTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of cortisol secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
Bergmann glial cell differentiationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of growth hormone secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
face morphogenesisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
intestinal epithelial cell migrationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cellular response to epidermal growth factor stimulusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
integrin bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
syntaxin bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
STAT family protein bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine oxidase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
iron ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdenum ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
protein homodimerization activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
FAD bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
phosphotyrosine residue bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
phosphoprotein phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
signaling receptor complex adaptor activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cell adhesion molecule bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
peptide hormone receptor bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
molecular adaptor activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseBos taurus (cattle)
peroxisomeXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine dehydrogenase complexXanthine dehydrogenase/oxidaseBos taurus (cattle)
cytoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID334194Inhibition of classical complement pathway activation at 4 uM assessed as complement modulation test2003Journal of natural products, Jan, Volume: 66, Issue:1
Complement-inhibiting iridoids from Morinda morindoides.
AID1850985Displacement of thiazole orange from human ILPR G4 quadruplex DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1867914Cytoprotective activity in human HK-2 cells assessed as reduction in uric acid-induced increase in branches and intracellular space at 100 uM by inverted light microscopic analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
AID467894Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml measured after 72 hrs by luciferase reporter gene assay2009Journal of natural products, Dec, Volume: 72, Issue:12
Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.
AID467895Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml after 72 hrs by luciferase reporter gene assay in presence of beta-glucosidase enzyme for 0.5 h2009Journal of natural products, Dec, Volume: 72, Issue:12
Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.
AID375989Antioxidant activity assessed as superoxide anion scavenging activity by xanthine oxidase oxidation system relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Vanillic acid glycoside and quinic acid derivatives from Gardeniae Fructus.
AID1741899Inhibition of recombinant human PTP1B using pNPP as substrate measured after 30 mins2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis and biological evaluation of geniposide derivatives as potent and selective PTPlB inhibitors.
AID1850983Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 100 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID358154Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 100 molar ratio after 48 hrs relative to TPA
AID375991Antioxidant activity assessed as inhibition of 2,2'-azobis(2-amidinopropane)dihydrochloride-induced lipid peroxidation at 3.125 ug/ml by ferric thiocyanate system relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Vanillic acid glycoside and quinic acid derivatives from Gardeniae Fructus.
AID469599Short term memory enhancement in human Abeta42 transgenic Drosophila alzheimers disease model dosed for 6 days by pavlovian olfactory learning assay after 8 days2009Journal of natural products, Aug, Volume: 72, Issue:8
Bioactive iridoid glucosides from the fruit of Gardenia jasminoides.
AID1850982Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 10 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1741901Inhibition of recombinant SHP2 (unknown origin) using pNPP as substrate measured after 30 mins2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis and biological evaluation of geniposide derivatives as potent and selective PTPlB inhibitors.
AID358152Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 1000 molar ratio after 48 hrs relative to TPA
AID1741900Inhibition of recombinant human TCPTP using pNPP as substrate measured after 30 mins2020European journal of medicinal chemistry, Nov-01, Volume: 205Synthesis and biological evaluation of geniposide derivatives as potent and selective PTPlB inhibitors.
AID1850984Displacement of thiazole orange from human ILPR G4 quadruplex DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID399059Immunosuppressive activity against human peripheral blood T cells assessed as inhibition of PMA and anti-CD28 monoclonal antibody-costimulated IL2 secretion at 50 ug/ml by ELISA2005Journal of natural products, Nov, Volume: 68, Issue:11
Immunosuppressive iridoids from the fruits of Gardenia jasminoides.
AID1850987Displacement of thiazole orange from human ILPR i-motif DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850976Binding affinity to human ILPR i-motif DNA assessed as change in melting temperature at 20 uM at pH 5.5 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID399060Immunosuppressive activity against human peripheral blood T cells assessed as inhibition of PMA and anti-CD28 monoclonal antibody-costimulated IL2 secretion at 100 ug/ml by ELISA2005Journal of natural products, Nov, Volume: 68, Issue:11
Immunosuppressive iridoids from the fruits of Gardenia jasminoides.
AID725307Inhibition of nitric oxide production in lipopolysaccharide-activated mouse RAW264.7 cells by Griess reaction based method2013Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4
Chemical constituents from the fruit of Gardenia jasminoides and their inhibitory effects on nitric oxide production.
AID1867884Anti-hyperuricemic activity against adenine and potassium oxonate-induced hyperuricemia Kunming mouse model assessed as blood urea nitrogen level at 200 mg/kg, po administered via gavage once daily for 2 weeks (Rvb = 9.88 +/- 1.21 mM)2022European journal of medicinal chemistry, Jul-05, Volume: 237Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
AID375992Inhibition of HIV1 recombinant integrase expressed in Escherichia coli2006Journal of natural products, Apr, Volume: 69, Issue:4
Vanillic acid glycoside and quinic acid derivatives from Gardeniae Fructus.
AID358155Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 10 molar ratio after 48 hrs relative to TPA
AID1850988Displacement of thiazole orange from human ILPR i-motif DNA at 10 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850974Binding affinity to human ILPR G4 quadruplex DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID358153Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA activation at 500 molar ratio after 48 hrs relative to TPA
AID1867913Cytoprotective activity in human HK-2 cells assessed as reduction in uric acid-induced cell remodeling at 100 uM by inverted light microscopic analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
AID735995Inhibitory activity of EV71 IRES co-transfected with EMCV IRES in human RD cells at 2 mg/ml after 24 hrs by luciferase reporter gene assay2013European journal of medicinal chemistry, Apr, Volume: 62Inhibition of enterovirus 71 infections and viral IRES activity by Fructus gardeniae and geniposide.
AID1850977Binding affinity to human 1BNA double stranded DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1867877Inhibition of bovine XOD assessed as inhibition of uric acid formation using xanthine as substrate preincubated with enzyme for 5 mins followed by substrate addition and measured for 30 mins by microplate reader analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
AID375988Antioxidant activity assessed as DPPH free radical scavenging activity relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Vanillic acid glycoside and quinic acid derivatives from Gardeniae Fructus.
AID1867906Antiinflammatory activity in hyperuricemic human HK-2 cells assessed as reduction in TNF-alpha level at 200 uM2022European journal of medicinal chemistry, Jul-05, Volume: 237Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
AID1850972Binding affinity to human telomeric 1ELN i-motif DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1867880Anti-hyperuricemic activity against adenine and potassium oxonate-induced hyperuricemia Kunming mouse model assessed as reduction in serum uric acid level at 200 mg/kg, po administered via gavage once daily for 2 weeks (Rvb = 318.16 +/- 3.31 uM)2022European journal of medicinal chemistry, Jul-05, Volume: 237Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
AID1867882Anti-hyperuricemic activity against adenine and potassium oxonate-induced hyperuricemia Kunming mouse model assessed as reduction in serum creatinine level at 200 mg/kg, po administered via gavage once daily for 2 weeks (Rvb = 87.62 +/- 0.67 uM)2022European journal of medicinal chemistry, Jul-05, Volume: 237Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
AID1850991Displacement of thiazole orange from human 1BNA double stranded DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID735998Antiviral activity against EV71 infected in human RD cells assessed as inhibition of viral infection at 2 mg/ml treated 24 hrs prior to infection measured after 72 hrs by WST-1 assay2013European journal of medicinal chemistry, Apr, Volume: 62Inhibition of enterovirus 71 infections and viral IRES activity by Fructus gardeniae and geniposide.
AID1850981Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850989Displacement of thiazole orange from human ILPR i-motif DNA at 100 equiv. at pH 5.5 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID735999Antiviral activity against EV71 infected in human RD cells assessed as cell survival rate at 1 to 2 mg/ml after 24 hrs by WST-1 assay2013European journal of medicinal chemistry, Apr, Volume: 62Inhibition of enterovirus 71 infections and viral IRES activity by Fructus gardeniae and geniposide.
AID1850979Displacement of thiazole orange from human telomeric IKF1 G4 quadruplex DNA at 100 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1867907Antiinflammatory activity in hyperuricemic human HK-2 cells assessed as reduction in IL-1beta level at 200 uM2022European journal of medicinal chemistry, Jul-05, Volume: 237Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
AID735997Antiviral activity against EV71 infected in human RD cells assessed as viral RNA transcript level at 1 mg/ml treated 24 hrs prior to infection measured after 24 hrs by real time RT-PCR analysis2013European journal of medicinal chemistry, Apr, Volume: 62Inhibition of enterovirus 71 infections and viral IRES activity by Fructus gardeniae and geniposide.
AID467899Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml after 72 hrs by luciferase reporter gene assay2009Journal of natural products, Dec, Volume: 72, Issue:12
Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.
AID735994Inhibitory activity of EMCV IRES co-transfected with EV71 5' UTR in human RD cells at 2 mg/ml after 24 hrs by luciferase reporter gene assay2013European journal of medicinal chemistry, Apr, Volume: 62Inhibition of enterovirus 71 infections and viral IRES activity by Fructus gardeniae and geniposide.
AID1850975Binding affinity to human ILPR i-motif DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850971Binding affinity to human telomeric IKF1 G4 quadruplex DNA assessed as change in melting temperature at 20 uM at pH 7.4 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850986Displacement of thiazole orange from human ILPR i-motif DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850978Displacement of thiazole orange from human telomeric IKF1 G4 quadruplex DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1850980Displacement of thiazole orange from human telomeric 1ELN i-motif DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID358156Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio after 48 hrs by trypan blue assay
AID467896Antiviral activity against HCV expressing E1E2 glycoprotein with Vpr-deficient HIV vector assessed as inhibition of viral entry in human Huh7 cells at 20 ug/ml after 72 hrs by luciferase reporter gene assay in presence of beta-glucosidase enzyme for 4 hrs2009Journal of natural products, Dec, Volume: 72, Issue:12
Lamiridosins, hepatitis C virus entry inhibitors from Lamium album.
AID1867905Antiinflammatory activity in hyperuricemic human HK-2 cells assessed as reduction in TGF-beta level at 200 uM2022European journal of medicinal chemistry, Jul-05, Volume: 237Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
AID1850973Binding affinity to human telomeric 1ELN i-motif DNA assessed as change in melting temperature at 20 uM at pH 5.5 by FRET assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID735996Antiviral activity against EV71 infected in human RD cells assessed as viral RNA transcript level at 2 mg/ml treated 24 hrs prior to infection measured after 24 hrs by real time RT-PCR analysis2013European journal of medicinal chemistry, Apr, Volume: 62Inhibition of enterovirus 71 infections and viral IRES activity by Fructus gardeniae and geniposide.
AID1850990Displacement of thiazole orange from human 1BNA double stranded DNA at 10 equiv. at pH 7.4 by fluorescent intercalator displacement assay2022Bioorganic & medicinal chemistry letters, 10-01, Volume: 73Identification of sugar-containing natural products that interact with i-motif DNA.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (488)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (2.25)18.7374
1990's16 (3.28)18.2507
2000's73 (14.96)29.6817
2010's280 (57.38)24.3611
2020's108 (22.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.43 (24.57)
Research Supply Index6.21 (2.92)
Research Growth Index5.39 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (1.81%)6.00%
Case Studies1 (0.20%)4.05%
Observational1 (0.20%)0.25%
Other485 (97.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]